Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss the key data on adjuvant and neoadjuvant therapy and review current and emerging treatment options for metastatic disease.
Jeffrey S. Weber, MD, PhD
Program Director
Allison Betof Warner, MD, PhD
Hussein Tawbi, MD, PhD
Released: September 28, 2021

Information on this Educational Activity

Program Director

Jeffrey S. Weber, MD, PhD

Deputy Director
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
Professor of Medicine
NYU Grossman School of Medicine
New York, New York

Jeffrey S. Weber, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Moderna, Novartis, and Pfizer.

Faculty

Allison Betof Warner, MD, PhD

Assistant Member
Assistant Attending Physician
Melanoma Service
Division of Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Allison Betof Warner, MD, PhD, has disclosed that she has received consulting fees from BluePath Solutions, Iovance, Nanobiotix, Novartis, Pfizer, and Shanghai Jo’Ann Medical Technology.
Hussein Tawbi, MD, PhD

Associate Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein Tawbi, MD, PhD has disclosed that he has received consulting fees from Bristol-Myers Squibb, Eisai, Genentech/Roche, Iovance, Karyopharm, Merck, Novartis, and Pfizer and funds for research support (paid to his institution) from Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, and Novartis.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Related Content

Expert podcast on second-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Expert podcast on key data and current FDA approvals of first-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue